Gilead Sciences, Inc. (GILD) stock
Close on Nov 11, 2026Market cap $210.52BP/E –Yield 1.86%
Gilead Sciences, Inc. grew revenue 6.5% to $30.99B over the twelve months to Sep 30, 2026. Operating income fell 122.5% to -$2.36B, moving the operating margin from 36.1% to -7.6%. Free cash flow was $13.78B, up 50.4% from a year earlier. At the latest close the market valued the company at $210.52B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $210.52B
- P/E ratio
- –
- Price to sales
- 6.79
- Price to book
- 16.14
- Dividend yield
- 1.86%
- Free cash flow yield
- 6.55%
Fundamentals
- Revenue
- $30.99B
- Net income
- -$3.86B
- EPS, diluted
- -$3.16
- Free cash flow
- $13.78B
- Book value per share
- $10.42
- Diluted shares
- 1.25B
Trading
- Next earnings
- Feb 9, 2027 (estimated, after the close)
- Previous close
- $170.87
- Open
- $169.45
- Day's range
- $168.37 – $170.48
- Volume
- 4,883,537
- Average volume (20 days)
- 6,975,670
- Index membership
- S&P 500, Nasdaq-100, Russell 1000, Russell 3000
- Beta (5 years)
- 0.43
- 52-week range
- $116.88 – $176.58
- RSI (14 days)
- 62.2
- Volatility (1 year)
- 27.5%
- Relative volume
- 0.78×
- WACC
- 7.0%
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, QQQ, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | GILD | S&P 500 | Difference | GILD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.3% | -2.4% | +14.7 pts | ||
| 3 months | +25.7% | -1.2% | +26.9 pts | ||
| Year to date | +40.8% | +12.3% | +28.5 pts | ||
| 1 year | +41.9% | +12.4% | +29.5 pts | ||
| 3 years | +145.7% | +78.8% | +66.9 pts | +34.9% | +21.4% |
| 5 years | +200.8% | +75.2% | +125.6 pts | +24.6% | +11.9% |
| 10 years | +216.4% | +311.1% | −94.8 pts | +12.2% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Gilead Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Results
About Gilead Sciences
Biological Products, (No Diagnostic Substances)
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and delivers therapies targeting life-threatening medical conditions. The firm concentrates its commercial and clinical efforts primarily on virology, oncology, and liver diseases. Its portfolio comprises treatments for HIV management and prevention, hepatitis, COVID-19, and several cancers, as well as specialized cell therapies and antifungal solutions. Gilead provides these medicines to patients globally, commercializing them mainly through pharmaceutical wholesale distributors, specialty distributors, direct clinical promotion to healthcare providers, and regional commercial partnerships.
Company profile, executives and historyGilead Sciences stock: common questions
What is Gilead Sciences's stock price?
GILD closed at $169.73 on Nov 11, 2026, down 0.67% on the day. Over the past 52 weeks it traded between $116.88 and $176.58.
What is Gilead Sciences's market cap?
Gilead Sciences was worth $210.52B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is GILD's P/E ratio?
Gilead Sciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.16), so it has no meaningful P/E ratio.
How much revenue does Gilead Sciences make?
Gilead Sciences reported revenue of $30.99B for the twelve months to Sep 30, 2026, up 6.5% from a year earlier.
Does Gilead Sciences pay a dividend?
Yes. Gilead Sciences paid $3.16 per share over the last twelve months, a yield of 1.86% at the latest price, and has raised its annual dividend 11 years in a row.
When does Gilead Sciences report earnings next?
Gilead Sciences is expected to report Q4 FY2026 results on Feb 9, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has GILD stock performed over the past year?
Including dividends, GILD returned +41.9% over the past year, against +12.4% for the S&P 500.
How many GILD shares are sold short?
21M shares were sold short at the latest FINRA report, 1.72% of the float, or 3.2 days of average trading volume.
Who are Gilead Sciences's competitors?
Companies most similar to Gilead Sciences by business, industry and size include AMGN, BIIB, GSK, VTRS, TEVA.
See a number that looks wrong?